Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial | Nature Medicine
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma | NEJM
YESCARTA® (axicabtagene ciloleucel) Now Approved Treatment | HCP Site
CAR T Cells: Second-Line Treatment Option for NHL? - NCI
CAR-T 'highly cost-effective' as second-line treatment for large B-cell lymphoma
تويتر \ Graham Collins على تويتر: "Dr Kersten: trials of Axi-Cel. Zuma-1 ongoing with current cohort mandating debulking chemo. Zuma-7 comparing autologous Tx approach with CART approach. Randomised studies planned with Tisag-Cel
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma | NEJM
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium | Journal of Clinical Oncology
Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma | Business Wire
Axi-cel vs SoC for R/R LBCL: ZUMA-7 primary analysis
Miguel Perales M.D. on Twitter: "#ASH21 Plenary - ZUMA-7 results: Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma #CARTcells https://t.co/embhPt2mkJ" / Twitter
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma - ScienceDirect
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta® in Large B-cell Lymphoma
ZUMA-7 - Capsule Summary Slidesets - Lymphomas and CLL - 2021 ASH Annual Meeting - Oncology - Clinical Care Options
Dr. Leslie on the Methods of the ZUMA-7 Trial in Relapsed/Refractory LBCL
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma | NEJM
Patient journey from screening to CAR T-cell infusion for JULIET and... | Download Scientific Diagram
Clinical Review Results - Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Clinical Report - NCBI Bookshelf
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial | Nature Medicine
EFS improvement with axi-cel CAR-T a 'breakthrough' in second-line treatment of DLBCL
ZUMA-7 Data Underscore Potential of CAR T-cell Therapy as Second-Line Standard in Relapsed/Refractory LBCL
